104 bölüm

This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*

Two Onc Docs Sam and Karine

    • Sağlık ve Fitness

This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*

    Genetic Syndromes Part 1

    Genetic Syndromes Part 1

    This week’s episode will be focusing on genetic syndromes with increased risk of malignancies. In Part 1 we discuss Li-Fraumeni, Lynch Syndrome, FAP, BRCA 1 and 2, and Cowden's syndrome.

    • 12 dk.
    Metastatic Kidney Cancer x Uromigos 2024 UPDATES (Part 2)

    Metastatic Kidney Cancer x Uromigos 2024 UPDATES (Part 2)

    Today’s episode we will cover 2024 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

    • 29 dk.
    Localized Kidney Cancer x Uromigos 2024 UPDATES (Part 1)

    Localized Kidney Cancer x Uromigos 2024 UPDATES (Part 1)

    Today’s episode we will cover 2024 updates for localized renal cell carcinoma (RCC). We will discuss risk factors, the presentation, staging, and treatment options. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

    • 16 dk.
    Testicular Cancer 2024 x Dr. Larry Einhorn Part 2 (Non-Seminoma)

    Testicular Cancer 2024 x Dr. Larry Einhorn Part 2 (Non-Seminoma)

    This week’s episode will be focusing on Testicular Cancer, including the treatment of Non-Seminomas. We are so honored to have Dr. Larry Einhorn here with us today and he provides key pearls, in addition to words of wisdom for trainees in oncology.

    • 24 dk.
    Testicular Cancer 2024 x Dr. Larry Einhorn Part 1 (Seminoma)

    Testicular Cancer 2024 x Dr. Larry Einhorn Part 1 (Seminoma)

    This week’s episode will be focusing on the risk factors, work-up, and staging of Testicular Cancer, as well as cover the treatment of Seminomas. We are so honored to have Dr. Larry Einhorn here with us today who is a legend when it comes to the treatment of germ cell tumors, and among many other accolades is Distinguished Professor of Medicine at the University of Indiana.

    • 31 dk.
    Hematopoietic Growth Factors

    Hematopoietic Growth Factors

    This week’s episode will be focusing on hematopoietic growth factors, including G-CSF, TPO agonists, and ESAs. This is another episode in our series on supportive care, and a highly testable and frequently discussed topics on consults and in clinic.

    • 13 dk.

En Popüler Sağlık ve Fitness Podcast’leri

Psikopatika
Podbee Media
Merdiven Altı Terapi
Deniz Dülgeroğlu
Terapist Koltuğu
Podbee Media
Psikiyatri ve Duvarın Ardı
Uzm. Dr. Cengiz Arca
Bi Kahvelik Sohbet
Tuba Dadaşoğlu
Unicornun Gozuyle
Cetin Cetintas

Beğenebilirsiniz

Plenary Session
Vinay Prasad, MD MPH
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
JAMA Clinical Reviews
JAMA Network
Core IM | Internal Medicine Podcast
Core IM Team
The Clinical Problem Solvers
The Clinical Problem Solvers
NEJM This Week
NEJM Group